CNS Pharmaceuticals (NASDAQ:CNSP) Stock Jumps 1.5% – Here’s WhyDefense World · Oct 4, 2026
CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks TranscriptSeeking Alpha · Sep 30, 2026
CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of GrowthAccesswire · Sep 1, 2026
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand ConferenceAccesswire · Aug 27, 2026
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic TransformationAccesswire · Aug 12, 2026CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.24 | -$0.38 | Miss |
| May 14, 2026 | -$5.37 | -$7.30 | Miss |
| Mar 31, 2026 | -$5.09 | -$5.09 | Beat |
| Nov 14, 2025 | -$6.63 | -$5.76 | Beat |
| Aug 14, 2025 | -$9.60 | -$6.42 | Beat |
| May 15, 2025 | -$24.00 | -$18.97 | Beat |